Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
DIAZ-LLOPIS, M. et al. Intravitreal injection of bevacizumab for pseudophakic cystoid macular edema resistant to steroids. Arch Soc Esp Oftalmol [online]. 2007, vol.82, n.7, pp.447-450. ISSN 0365-6691.
Clinical case: A 71-year-old man presented with pseudophakic cystoid macular edema (PCME) and a visual acuity (VA) of 0.1. He had been treated with 2 intra-vitreal injections of triamcinolone acetonide (4 mg) 16 months previously. One week after the intra-vitreal injection of bevacizumab (1.25 mg), VA improved to 0.33, and the OCT demonstrated decreased macular thickness. Two months after the injection, no ocular complications were observed, VA was 0.5 and the OCT showed a significant reduction in the retinal thickness. Conclusion: Intra-vitreal injection of bevacizumab may be an additional tool for the treatment of therapy-resistant PCME.
Palabras clave : Bevacizumab; intra-vitreal injection; pseudophakic cystoid macular edema; cataract surgery; corticoid resistant.